Cargando…

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer

PURPOSE: The claudin 18.2 (CLDN18.2) antigen is frequently expressed in malignant tumors, including pancreatic ductal adenocarcinoma (PDAC). Although CLDN18.2-targeted CAR-T cells demonstrated some therapeutic efficacy in PDAC patients, further improvement is needed. One of the major obstacles might...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yifan, Sun, Yansha, Wang, Peng, Li, Songling, Dong, Yiwei, Zhou, Min, Shi, Bizhi, Jiang, Hua, Sun, Ruixin, Li, Zonghai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091631/ https://www.ncbi.nlm.nih.gov/pubmed/37046312 http://dx.doi.org/10.1186/s12967-023-04080-z

Ejemplares similares

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
por: Luo, Hong, et al.
Publicado: (2019)

An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment
por: Wang, Yi, et al.
Publicado: (2019)

Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
por: Di, Shengmeng, et al.
Publicado: (2019)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment
por: Lin, Yuli, et al.
Publicado: (2019)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors
por: Sun, Yansha, et al.
Publicado: (2022)

Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
por: Bughda, Reyisa, et al.
Publicado: (2021)

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
por: Das, Shipra, et al.
Publicado: (2023)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017)

TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
por: Nai, Yaru, et al.
Publicado: (2021)

A promising antitumor method: Targeting CSC with immune cells modified with CAR
por: Huang, Binjie, et al.
Publicado: (2022)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
por: Yang, Quanjun, et al.
Publicado: (2022)

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
por: Li, Fanfan, et al.
Publicado: (2022)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer
por: Liang, Zhen, et al.
Publicado: (2021)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
por: Liu, Shiyu, et al.
Publicado: (2023)

ATRT-17. CAR T CELL THERAPY TARGETING CLAUDIN-6 IS EFFECTIVE IN CELLULAR AND XENOGRAFT MODELS OF ATYPICAL TERATOID/RHABDOID TUMOR
por: Madsen, Peter, et al.
Publicado: (2023)

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions
por: Dong, Zhenyuan, et al.
Publicado: (2020)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
por: Zhong, Weixiang, et al.
Publicado: (2022)

Immunotherapy of targeting MDSCs in tumor microenvironment
por: Sui, Hongshu, et al.
Publicado: (2022)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Catechins and antitumor immunity: Not MDSC’s cup of tea
por: Santilli, Giorgia, et al.
Publicado: (2013)

Gene Targets of CAR-T Cell Therapy for Glioblastoma
por: Wang, Chaoqun, et al.
Publicado: (2023)

Incorporation of functional elements enhances the antitumor capacity of CAR T cells
por: Qin, Le, et al.
Publicado: (2017)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Targeting of intracellular oncoproteins with peptide-centric CARs
por: Yarmarkovich, Mark, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v1c2cdvnf17r5l5v7okslmf2ej